Prediction of dynamical drug sensitivity and resistance by module network rewiring-analysis based on transcriptional

Tao Zeng1, Diane Catherine Wang2, Xiangdong Wang3

  • 1Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.

Insights

Module network rewiring-analysis (MNR) reveals how biological modules reorganize during drug treatment. This approach identifies biomarkers for predicting drug sensitivity and resistance in complex diseases.

Area of Science:

  • Systems biology
  • Pharmacogenomics
  • Computational biology

Background:

  • Understanding functional reorganization at the network level is crucial for deciphering drug responses and therapeutic mechanisms.
  • Existing methods often focus on molecular networks or individual genes, potentially missing higher-level functional changes.

Purpose of the Study:

  • To introduce a novel model and framework, module network rewiring-analysis (MNR), for characterizing functional reorganization in complex biological systems.
  • To systematically study dynamic drug sensitivity and resistance during therapeutic interventions.

Main Methods:

  • Developed and applied the module network rewiring-analysis (MNR) framework to analyze functional reorganization at the module network level.
  • Investigated gene expression data from Hepatitis C virus patients undergoing Interferon therapy.
  • Focused on module network rewiring rather than individual molecular analysis.

Main Results:

  • MNR identified consistent module genes that revealed novel genotypes associated with drug sensitivity, outperforming traditional differential gene expression analyses.
  • Functional connections and reconnections among modules, bridged by biological pathways, were found essential for effective drug response.
  • Hierarchical structures of the temporal module network served as spatio-temporal biomarkers for monitoring therapy efficacy, toxicity, and resistance.

Conclusions:

  • MNR is an effective tool for identifying module biomarkers and predicting dynamic drug sensitivity and resistance.
  • The framework aids in characterizing complex dynamic processes underlying therapy response.
  • Provides systematic biological insights for pharmacogenomic applications.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
219